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Background: Telomere shortening is a normal age-related process. However, premature shortening of telomeres
in leukocytes – as has been reported in depression – may increase the risk for age-related diseases. While previous
studies investigated telomere length in peripheral blood mononuclear cells (PBMCs) as a whole, this study
investigated specific changes in the clonal composition of white blood cells of the adaptive immune system
(CD4+ helper and CD8+ cytotoxic T lymphocytes, and CD20+ B lymphocytes).
Methods: Forty-four females with a history of unipolar depression were investigated and compared to fifty
age-matched female controls. Telomere lengths were compared between three groups: 1) individuals with a history
of depression but currently no clinically relevant depressive symptoms, 2) individuals with a history of depression
with relevant symptoms of depression, and 3) healthy age-matched controls. Telomere length was assessed using
quantitative fluorescence in situ hybridization (qFISH).
Results: Both groups with a history of unipolar depression (with and without current depressive symptoms)
showed significantly shorter telomeres in all three lymphocyte subpopulations. The effect was stronger in CD8+
and CD20+ cells than in CD4+ cells. Individuals with a history of depression and with (without) current symptoms
exhibited a CD8+ telomere length shortening corresponding to an age differential of 27.9 (25.3) years.
Conclusions: A history of depression is associated with shortened telomeres in the main effector populations of
the adaptive immune system. Shorter telomeres seem to persist in individuals with lifetime depression
independently of the severity of depressive symptoms. CD8+ cytotoxic T cells and CD20+ B cells seem to be
particularly affected in depression. The total number of depressive episodes did not influence telomere length in
the investigated adaptive immune cell populations.
Keywords: Depression, Telomere shortening, Aging, Stress, ImmunosenescenceBackground
Depression may be associated with an accelerated cellular
aging of the immune system, contributing to a higher
morbidity and mortality due to an earlier onset of age-
related diseases such as cardiovascular diseases [1], and
cancer [2]. Telomere length (TL) represents a biological
marker of aging [3]. Telomeres shorten in healthy aging in
CD4+ T helper, CD8+ cytotoxic T cells, and antibody-
producing B cells at a yearly rate of 19-35 base pairs [4].
Telomere shortening increases the risk for age-related dis-
eases such as cardiovascular diseases [1] and cancer [5].
Animal studies showed that chronic stress accelerates* Correspondence: alexander.karabatsiakis@uni-ulm.de
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article, unless otherwise stated.telomere shortening [6]. In human studies, shorter telo-
meres were found in pessimistic women [7], after psycho-
logical stress, including a history of early maltreatment
[8], severe social deprivation [9], and in patients with
mood disorders [10,11]. Epel et al. [12] showed telomere
shortening in individuals with greater environmental ex-
posure to stress (mothers with a chronically ill child),
which was not due to changes in the subcomposition of
peripheral blood mononuclear cells (PBMCs). In sum,
several studies point towards an acceleration of cellular
aging due to psychological distress. One contributing
factor how psychological stress might be translated to
accelerated aging is via increased rates of reactive oxy-
gen (ROS) and reactive nitrogen species (RNS). Both
lead to unspecific damage of intracellular compartmentsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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meres [13,14]. Cells counteract these processes with a lim-
ited potency of antioxidant protection [15]. Another
contributing factor of shorter telomeres in depression
might be the reported increase in the total number of im-
mune cells in depression [16] as the higher cell division
rates would lead to increasing cell numbers implying an
accelerated loss of telomeres. Finally, due to the higher
risk of suffering from physical diseases, depressive individ-
uals might possibly have a higher wear and tear (due to
clonal expansion) of adaptive immune cells, contributing
to telomere shortening [10].
To know which specific cells out of the different cell
types that PBMCs consist of are most affected by telo-
mere loss, probably reflecting premature immunological
aging, would be of high scientific relevance. Only two
studies so far differentiated telomere length attrition in
different cell types in the context of healthy [17] and
pathological aging [18]. Results suggest that the (CD8+
cytotoxic) T cells are most affected by premature aging.
This study investigated telomere length in cells of the
adaptive immune system, namely CD4+ helper T cells,
CD8+ cytotoxic T cells and CD20+ B cells in individuals
with a history of unipolar depression vs. controls. Three
groups were distinguished: 1) individuals with a history
of unipolar depression and no clinically relevant symptoms
of depression, 2) individuals with a history of unipolar de-
pression with relevant symptoms of depression, and 3)
age-matched healthy controls. We hypothesized that in-
dividuals with a history of depression (both with and
without relevant symptoms of depression) show signifi-
cantly shorter telomere length in all three lymphocyte
subpopulations in comparison to the control group.
Methods
Participants
Forty-four individuals with at least one episode of uni-
polar depression (ICD-10 diagnosis: F32.0-2, F32.4;
F33.0-2, F33.4), as determined by standard clinical evalu-
ation and documented in clinical records, and 50 control
subjects who reported no current or past psychiatric
disorder participated in the study. Both groups were
matched for age (range: 39-66 years) and education.
Middle to age-progressed individuals were recruited as
depression-related telomere shortening was assumed to
have an increasing effect with age. To exclude gender-
specific effects on telomere shortening all participants
were females recruited by newspaper announcement and
public advertisements. Following an initial telephone
screening in which basic exclusion criteria were applied
(age, history of stroke, head injuries or trauma, epilepsy
or any similar neurologic disease, loss of consciousness
for more than 10 minutes), qualifying participants were
invited to donate 50 ml of peripheral blood by venouspuncture. Depressive symptoms were assessed by the Beck
Depression Inventory (BDI) [19]. A sum score below 14 in
the BDI has been suggested as an indicator of remission
[20]. Based on the BDI score, subjects with lifetime de-
pression were divided into two subgroups: 1) Individuals
with irrelevant severity of depressive symptoms (BDI ≤ 13,
[IS]) and 2) lifetime depressed with relevant depressive
symptoms (BDI ≥ 14, [RS]). Participants were further
interviewed about their medical history. Participants who
reported a lifetime or concurrent general medical, neuro-
logical or psychiatric disorders (e.g. dementia, Parkinson’s
disease, non-comorbid anxiety disorders including post-
traumatic stress disorder, Borderline personality disorder
or different types of phobia) were excluded from the
study. Inclusion criteria for the group of lifetime depressed
was at least one unipolar depressive episode and a mini-
mum period of six months since the last hospitalization in
a psychiatric clinic according to the release letter they pro-
vided. The age at first depressive episode and the total
number of episodes were assessed using the provided clin-
ical documentation of hospitalization. In addition, partici-
pants were interviewed about their clinical history. All
participants gave written informed consent and received a
compensation of 50 €. The study was approved by the
Ethics Committee of the Hannover Medical School.
Isolation of leukocyte subfractions and purity control
Blood samples were taken into EDTA buffered blood
collection tubes (Sarstedt, Germany) and processed with
standard procedures by Ficoll-Paque (GE Healthcare,
USA) dense-gradient centrifugation to isolate buffy coat.
Blood was collected between 10 am and 1 pm. Participants
were allowed to eat and drink in the morning. Leukocytic
subpopulations (CD4+ and CD8+ T- and CD20+ B-cells)
were isolated by MACS separation using appropriate mag-
netically labeled antibody beads (Miltenyi Biotech, USA)
following the manufacturer’s protocol. The purity of the
isolated cell fractions was evaluated using appropriate
antibodies (Miltenyi Biotech, USA) at distinct intervals by
cytometry performed on randomly selected isolates. As
telomeres were measured in isolated subpopulations of
white blood cells (WBCs), possible stress-induced alter-
ations in the composition of WBCs can be excluded and
cannot influence the telomere length results observed in
this study. Cells were washed three times with standard
phosphate buffered saline followed by fixation using a
methanol/glacial acetic acid solution (3:1). Fixated cells
were stored at -80°C prior to fluorescence microscopy ana-
lysis. TL was assessed using 105 cells per sample dropped
onto superfrost slides (Menzel-Gläser, Germany).
Telomere length analysis
Quantitative fluorescence in situ hybridization (qFISH)
was performed using peptide nucleic acid telomere
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the fluorescent dye Cy-3. The resulting telomere fluores-
cence intensity (TFI) signal correlates with TL. Co-
staining with DAPI (Vectashield, USA) was performed
to ensure the integrity of the cells by excluding false-
positive perinuclear signals. Digital images were cap-
tured with a thousandfold optical magnification by a
digital camera. The camera was mounted on a fluores-
cence microscope equipped with the appropriate Cy3-
specific filters and connected to the Leica image control
software (Leica microscope DM5000B, Leica, Germany).
The optimal exposure time was determined prior to the
study by trial and error using corresponding leukocytic
subcells of one 30 years old healthy male donor that
were also used as an internal control and reference (set
to TFI = 100%). By this means image capturing was per-
formed under standardized technical conditions (exposure
time: 250 milliseconds; microscope sensitivity threshold
level = 2). TFI was assessed in monochrome images relat-
ing telomere length to pixel brightness. The image acqui-
sition software TFL-TeloV2 [21] was used to estimate TFI.
Telomere length was calculated as the percentage differ-
ence between the mean TL of the corresponding cell
population from the internal control and the individual
mean TL of each set of cells from one subject. Telomere
length was estimated in 75 cells of the individual leukocyte
subset per subject. Samples with less than 75 assessed cells
were excluded from analysis (see Table 1).
Statistics
Statistical analyses were performed using R 3.0.2 [22].
Linear model residuals were tested for normality [23]
and equality of variance [24]. We used Kruskal-Wallis
or Wilcoxon tests when preconditions for ANOVA were
not fulfilled.
Results
Demographical data and clinical assessment
Groups did not differ with respect to age or education
(see Table 1). Furthermore, IS and RS groups did not dif-
fer significantly in mean age at the first depressive epi-
sode or in total number of depressive episodes. As
would be expected, the three groups differed signifi-
cantly in the BDI: controls showed lower BDI compared
to the IS group, which in turn showed lower BDI than
the RS group. IS and RS groups did not differ on SSRI
intake. The three groups did not differ in L-thyroxine in-
take for the treatment of hypothyreosis.
Statistical analysis of telomere length
For each cell type, we calculated three different models
with the dependent variable telomere length: 1) with a
factor groups alone, 2) with a factor group and a covariate
age with homogeneous slopes between groups, and 3)with an interaction between group and age. The model
with a homogeneous influence of age yielded the smallest
Akaike information criterion (AIC) [25] for CD8+ and
CD20+ cells, whereas the model with an interaction be-
tween groups and age yielded a very slightly lower AIC for
CD4+ (-64.7 without, -65.1 with the interaction). We re-
port on the model with homogeneous age influence for all
cell types below, as results do not change appreciably with
the other candidate models. The Shapiro-Wilk test indi-
cated that residuals from all three models were not nor-
mally distributed for the CD4+ and the CD20+, but a
Kruskal-Wallis nonparametric test yielded similar results
for group effects. In addition, we verified the results by
substituting the BDI for group membership in our models
while controlling for age, although this modification led to
clearly larger AICs.
For CD4+ cells, there was a significant effect of group,
F(2,87) = 8.54, p = .0004, η2 = .16, η2p = .16, but not of age,
F(1,87) = .31, p = .58, η2 = .003, η2p = .004. Post hoc tests
revealed significant differences between CG and IS, F
(1,68) = 12.28, p = .0008, as well as between CG and RS,
F(1,64) = 11.24, p = .001, but not between IS and RS, F
(1,41) = .15, p = .70. For CD8+ cells, there were signifi-
cant effects of group, F(2,81) = 20.89, p < .0001, η2 = .29,
η2p = .34, and of age, F(1,81) = 20.63, p < .0001, η
2 = .14,
η2p = .20. Post hoc tests revealed significant differences
between CG and IS, F(1,65) = 28.86, p < .0001, as well
as between CG and RS, F(1,58) = 24.32, p < .0001, but
not between IS and RS, F(1,38) = .21 , p = .65. To com-
pare the TL reduction observed in the IS and RS to the
one associated with aging, the coefficient estimate of the
linear model for TL corresponding to each group (-.167
for IS, -.184 for RS), giving the group effect, was divided
by the coefficient estimate for age (-.00657), giving the
TL reduction per year of age (see Figure 1). To assess
the variability of this statistic, it was bootstrapped 10,000
times. The TL reduction in IS (RS) participants corre-
sponded to the reduction in control participants -.167/-
.00657 = 25.3 (-.184/-.00657 = 27.9) years older (slight
differences due to floating point arithmetic and round-
ing), bootstrapped 95% confidence interval 13.9-58.6
(12.3-66.9). For CD20+ cells, there were significant
effects of group, F(2,78) = 17.82, p < .0001, η2 = .30,
η2p = .31 and age, F(1,78) = 7.03, p = .01, η
2 = .06, η2p = .08.
Post hoc tests revealed significant differences between
CG and IS, F(1,63) = 28.64, p < .0001, as well as between
CG and RS, F(1,56) = 12.79, p = .0007, but not between IS
and RS, F(1,36) = .79, p = .38. As expected, the BDI had
significant effects on telomere lengths in all three cell
types: F(1,85) = 12.04, p = .0008, η2 = .12, η2p = .12 for
CD4+, F(1,79) = 21.53, p < .0001, η2 = .18, η2p = .21 for CD8+
and F(1,76) = 7.50, p = .008, η2 = .09, η2p = .09 for CD20+.
The total number of past depressive episodes (CD4+:
p = .95, CD8+: .27, CD20+ 0.83), antidepressant medication
Table 1 Results of the clinical assessment and telomere length (TL) comparison between control subjects (CG), lifetime
depressed with irrelevant symptoms (IS) and with relevant symptoms of depression (RS)
Group N Mean SD Overall test CG vs. IS IS vs. RS
Age (years) CG 50 51.1 8 χ22 = 2.10,
IS 24 53.1 7.2 p = .35
RS 20 53.8 7.6
Education (years) CG 50 15.1 2.4 χ22 = 3.05,
IS 24 14.1 2.1 p = .22
RS 20 14.2 2.9
Age at first depressive episode (years) CG 50 -
IS 24 37.2 12.6 t36.8 = 1.33,
RS 20 31.5 15.4 p = .19
Total depressive episodes CG 50 - -
IS 24 2.4 1.0 W = 176.5,
RS 20 3.2 2.1 p = .27
BDI CG 50 3.2 2.8 χ22 = 53.7, W = 253, W = 5.5,
IS 24 7.5 4.8 p < .0001 p = .0003 p < .0001
RS 20 21.7 7.4
SSRI/ SNRI intake CG 0 of 50
IS 10 of 24 χ22 = .33,
RS 9 of 20 p = .56
L-Thyroxine intake CG 3 of 50 χ22 = 1.26,
IS 1 of 24 p = .53
RS 0 of 20
CD4+ TL (%) CG 48 67.77 16.05 See text for detailed models and results
IS 24 55.06 15.73
RS 20 53.09 17.88
CD8+ TL (%) CG 45 68.7 13.69 See text for detailed models and results
IS 24 51.1 11.98
RS 17 48.76 13.07
CD20+ TL (%) CG 44 68.83 16.83 See text for detailed models and results
IS 23 47.44 9.44
RS 16 50 13.69
Hypertension CG 1 of 50
IS 1 of 24
RS 2 of 20
TL of the reference sample (30 years old healthy male subject) was set to 100%. TL of CD4+, CD8+, and CD20+ cells given in % related to the reference. BDI, Beck
Depression Inventory; SSRI, selective serotonine reuptake inhibitors; SNRI, serotonine and norepinephrine reuptake inhibitors; L-Thyroxine, treatment for
hypothyreosis.
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and L-thyroxine intake (CD4+: p= .26, CD8+: p = .57,
CD20+: p = .63) did not change the pattern of results or be-
came significant when included in models.
Discussion
Individuals with a history of unipolar depression (whether
with or without clinically relevant symptoms of depres-
sion) exhibited shorter telomeres in the three analyzedleukocyte subsets (CD4+ T helper cells, CD8+ cytotoxic T
cells, and CD20+ B cells). As we investigated telomere
length in subpopulations, the telomere length results
cannot be influenced by stress-induced alterations in
the composition of WBCs, which has been reported in
stress- and trauma-related research [26,35]. However,
the common investigation of PBMCs as a whole in con-
trast to subpopulations might explain some of the in-
consistencies in telomere-related findings in depression.
Figure 1 Between-group comparison of telomere length and age-related changes in adaptive immune cells. Top left: boxplot of
telomere lengths by group and cell type. P values for groups as calculated in ANOVAs, with age as a covariate. Outliers were included into the
analysis. Top right, bottom left and bottom right: observed telomere lengths per cell type in CD4+, CD8+, and CB20+ lymphocytes (as percentages of
telomere lengths of a reference sample, see text) together with group-wise model fits against age (lines). Model fits span ages observed within each
group. CG: control group; IS: lifetime depressed with irrelevant symptoms of depression (BDI ≤ 13); RS: lifetime depressed with relevant symptoms of
depression (BDI ≥ 14).
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effect in CD8+ and CD20+ than in CD4+ cells. Our re-
sults support the assumption of a systemic effect of de-
pression on telomere length in the adaptive immune
system [27]. The IS group, although they did not show
clinically relevant depressive symptoms any more, and in
particular the RS group were still significantly more
depressed than the control group. As both groups didnot differ significantly in telomere length, depression-
associated TL shortening did not significantly recover
since the last depressive episode in comparison to the
controls – assuming no differences in pre-depression TL.
Our results support the findings of Verhoeven and col-
leagues [28] who also investigated telomere length in de-
pression and found no differences between current and
remitted depressed individuals. However, we can of course
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Future studies should longitudinally follow up after remis-
sion of depression.
Limitations
We did not assess body mass index, nutrition, and life
style factors (tobacco use, alcohol consumption), which
might also influence telomere length. We also did not
assess the menstrual/hormonal status of participants,
hypertension or cardiovascular diseases, all of which may
influence mood and contribute to the etiology of depres-
sion [29]. As only women were investigated in this study,
the findings cannot be extrapolated to men. Gender-
specific differences in telomere length dynamics should
be investigated in the future. Participants were asked
about current medication intake but not about lifetime
medication. Furthermore, we did not assess the effect of
nutritional supplements on telomere length dynamics.
This would be an interesting aspect for further investi-
gations. In addition, we assessed the age at depression
onset and the total number of depressive episodes only
based on the provided clinical documentation. Although
our findings that the number of depressive episodes did
not influence telomere length is in line with the work of
Hartmann and colleagues [30] who reported that telo-
mere shortening in depression is independent from ill-
ness duration, we cannot rule out that the assessed
information was rather unreliable and thus might have
distorted a true effect of disease duration as well as
number of depressive episodes on telomere length.
Similarly, we did not assess in the completely remitted
depressed group the time interval since the last depres-
sive episode. This should be investigated in future stud-
ies. Finally, both clinical groups still, even those without
clinically relevant symptoms, showed higher depressive
symptoms than the control group. Residual depressive
symptomatology is often observed in individuals with a
history of unipolar depression [31-34]. Thus, it is pos-
sible, although unlikely, that in both clinical groups
telomere length could recover, if they reached BDI
scores comparable to those of controls. Therefore longi-
tudinal studies with depressed individuals over the
course of treatment should investigate telomere dynamics
in healthy and psychopathological aging of the (adaptive)
immune system.
Future studies
In future studies it would be interesting to further subdiv-
ide cytotoxic T cells in naïve and memory T cells. Naïve T
cells decrease with healthy aging [35]. Indeed, a specific
reduction in naïve cytotoxic T cells has been observed in
patients with posttraumatic stress disorder [36] suggesting
an accelerated aging of the adaptive immune as a conse-
quence of (traumatic) stress. Furthermore, future studiesshould also assess telomerase activity, the enzyme that
elongates telomeric structures, in cells of the adaptive
immune system, as we know by now that telomerase is
active in stimulated lymphocytes [17,4]. Further, Choi
and colleagues have shown that cortisol impairs telomerase
activity in human T lymphocytes [37]. Finally, telomere
shortening might be observed in various psychiatric dis-
orders (e.g. anxiety disorders [38], post-traumatic stress
disorder [8]) and should therefore be investigated in
various stress-related psychiatric diagnoses in the fu-
ture. Moreover, future studies should also investigate
telomere shortening not only in immune cells but also
in cells of different organs. Indeed, telomeric length be-
tween different organs correlates in an individual [39,40].
Therefore, it is possible that individuals with a history of
depression would also show shorter telomeres in other or-
gans and systems.
Conclusions
Individuals with a history of depression show shortened
telomeres in the main effector populations of the adaptive
immune system and shorter telomeres seem to persist in-
dependently of the severity of depressive symptoms. CD8
+ cytotoxic T cells and CD20+ B cells seem to be particu-
larly affected in depression. The total number of clinically
documented depressive episodes did not influence the
telomere length in depressed individuals.
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